About the forum

The purpose of RDAF is to serve as a platform to exchange ideas and define actions to raise awareness of rare diseases and to improve access to treatment and patient care in Switzerland.


RDAF brings together experts from various stakeholders in the field of rare diseases.

RDAF Brochure.pdf


Latest News

SMA Schweiz joins the Rare Disease Action Forum

News - 26 March 2021

We are proud to welcome SMA Schweiz as the newest member of the Rare Disease Action Forum. Reinforcing RDAF’s multi-stakeholder approach, they will be joining our other members from industry, patient organizations, healthcare professionals, and research organizations. We look forward to their contribution to the collaborative efforts at the RDAF multi-stakeholder platform. Together we will continue our efforts to improve access to diagnosis, treatment and care for patients with rare diseases in Switzerland.

The RDAF submitted its statement for the public consultation on the ordinances for the revision of the Swiss Invalidity Insurance

On 19 March 2021, the RDAF submitted its statement to the Federal Social Insurance Office (BSV, Bundesamt für Sozialversicherungen) for the public consultation on the adjustment of various ordinances which are needed to implement the revised Swiss Invalidity Insurance (IV, Invalidenversicherung).


In its submission, the RDAF recalls that the main objective of the IV (integration/reintegration) is fundamentally different from the objectives of the obligatory health insurance (OKP, obligatorische Krankenpflegeversicherung). For the RDAF, this objective must remain the top priority of the IV, although a certain degree of harmonization between the IV and the OKP is desirable (e.g. for the benefit assessment of medicines).


The RDAF advocates for the continuity of existing services and the rapid reimbursement of new therapies to be guaranteed. With this aim in view, the RDAF calls for simplified, more efficient and faster processes.


For the RDAF, equal access to treatment is of paramount importance both in the IV and the OKP. The existence of a “funding gap” between the two systems is unacceptable from a patient’s perspective, especially since the National Concept for Rare Diseases sets a seamless transition from the IV to the OKP as a specific goal.


The RDAF full statement is accessible here.